SCHEMBL16752184

SCHEMBL16752184

Cc1ccc(S(=O)(=O)n2nc(C)c3ccc(CC(=O)O)cc32)cc1

nearest known ligand 0.54

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 12/20 0.54
PTGDR2 Q9Y5Y4 3/20 0.44
MAPT P10636 3/20 0.44
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16771338 0.85 KMT2A (0.43) SLC22A12PTGDR2MAPTALDH1A1HSD17B10
SCHEMBL1099865 0.77 MAPT (0.57) MAPTKDM4EALDH1A1HSD17B10MEN1
SCHEMBL2144861 0.77 MAPT (0.50) MAPTKDM4EALDH1A1MEN1GAA
SCHEMBL8604227 0.77 SLC22A12 (0.55) SLC22A12PTGDR2KDM4EALDH1A1HPGD
SCHEMBL1099850 0.74 ALDH1A1 (0.49) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL12253486 0.74 SLC9A1 (0.56) MAPTKDM4EALDH1A1MEN1GAA
SCHEMBL14678507 0.71 RORC (0.44) PTGDR2MAPTHSD17B10MEN1GAA
SCHEMBL11975875 0.71 SLC22A12 (0.71) SLC22A12
SCHEMBL16752337 0.70 KMT2A (0.45) SLC22A12PTGDR2MAPTALDH1A1HPGD
SCHEMBL11977217 0.70 SLC22A12 (1.00) SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3444238-B1 PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS SATO PHARMA (JP) 2021-12-08 EP disclosed
EP-3444238-A2 PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS Sato Pharmaceutical Co., Ltd. (JP) 2019-02-20 EP disclosed
EP-2878594-B1 DIFLUOROMETHYLENE COMPOUND SATO PHARMA (JP) 2018-11-28 EP disclosed
US-9650380-B2 Difluoromethylene compound SATO PHARMACEUTICAL CO., LTD. (JP) 2017-05-16 US disclosed
US-20170044158-A1 DIFLUOROMETHYLENE COMPOUND SATO PHARMACEUTICAL CO., LTD. (JP) 2017-02-16 US disclosed
US-9512119-B2 Difluoromethylene compound SATO PHARMACEUTICAL CO., LTD. (JP) 2016-12-06 US disclosed
US-20150191463-A1 DIFLUOROMETHYLENE COMPOUND SATO PHARMACEUTICAL CO., LTD. (JP) 2015-07-09 US disclosed
EP-2878594-A1 DIFLUOROMETHYLENE COMPOUND Sato Pharmaceutical Co., Ltd. (JP) 2015-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044158-A1 DIFLUOROMETHYLENE COMPOUND XDH, URB2, MNAT1 SLC22A12 590/4885PTGDR2 4246/4885MAPT 1841/4885
US-20150191463-A1 DIFLUOROMETHYLENE COMPOUND XDH, SULT1A1, RFT1 SLC22A12 574/4885PTGDR2 3980/4885MAPT 2405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.